KRAS and adenocarcinoma: In non-adenocarcinoma cases, one EGFR Ex.19 deletion, one KRAS G12C mutation, two KRAS other mutations, and one MET Ex.14 skipping were detected with the ODxTT; meanwhile, no driver alterations were detected with the AmoyDx-multi test.